Market Research Logo

Global Migraine Drugs Market 2016-2020

About Migraines

A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

Technavio’s analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Endo International
  • GlaxoSmithKline
  • Impax
  • Pfizer
Other prominent vendors
  • Abbott
  • Aegis Therapeutics
  • Aeriel BioPharma
  • Alder Biopharmaceuticals
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • CoLucid
  • Dr. Reddy’s Laboratories
  • Eisai
  • Eli Lilly
  • Ethypharm
  • IntelGenx
  • Johnson & Johnson
  • Klaria
  • Kowa Pharmaceuticals America
  • Luitpold Pharmaceuticals
  • Meda
  • Merck
  • OptiNose
  • Pfizer
  • Pozen
  • Raptor
  • RedHill
  • SUDA
  • Teva
  • TG Therapeutics
  • NValeant
  • Winston Pharmaceuticals
  • Zogenix
Market driver
  • Growing awareness about migraine and its treatment options
  • For a full, detailed list, view our report
Market challenge
  • Lack of proper diagnosis
  • For a full, detailed list, view our report
Market trend
  • Antimigraine devices and headbands
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Migraine Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Migraine Drugs Market: Allergan, Endo International, GlaxoSmithKline, Impax, and Pfizer.

Other Prominent Vendors in the market are: Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, and Zogenix.

Commenting on the report, an analyst from Technavio’s team said: “One market trend to watch for is the development and availability of antimigraine devices and headbands. Antimigraine drugs are associated with various side effects and show less tolerance among the patients. Thus, the need for new treatment options has led to the development of various devices in the market. Antimigraine devices and headbands are being increasingly preferred for the prevention of migraines. The FDA has approved Cerena Transcranial Magnetic Stimulator and the Cefaly Transcutaneous Electrical Nerve Stimulation device for migraine treatment. Cefaly is a plastic headband, which can be worn across the forehead.”

According to the report, a key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. The occurrence of side effects is the major reason that limits the use of migraine drugs. Moreover, there are still high levels of unmet need existing in certain niche populations, especially in patients who do not respond satisfactorily to triptans or patients for whom triptans are contraindicated.

Further, the report states that a challenge that could have a big impact on market growth is the lack of proper diagnosis of migraines.

Companies Mentioned

Allergan, Endo International, GlaxoSmithKline, Impax, Pfizer, Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, Zogenix.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Types
    • Cause
    • Management
    • Epidemiology
      • Table Percentage of migraine sufferers worldwide by gender
    • Economic burden
  • Pipeline analysis
    • Table Global migraine drugs market: Pipeline portfolio
    • Semprana
    • Rizaport
    • Sumatriptan
    • DFN-11
    • Lasmiditan
    • SUD001
    • AMG 334
    • DFN-02
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global migraine drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of treatment
    • Preventative
      • Table Preventative medications based on efficacy of drugs
    • Abortive
      • Table Medications used based on severity of migraines
      • Table Percentage share of preventative and abortive migraine medications in US 2015
  • Market segmentation by therapeutic class
    • Table Segmentation of global migraine drugs market by therapeutic class 2015
    • Triptans
      • Table Market share of triptans by ROA 2015
    • Ergot alkaloids
    • Other
  • Geographical segmentation
    • Global migraine drugs market by geographical segmentation 2015-2020
      • Table Global migraine drugs market by geography 2015
      • Table Global migraine drugs market by geography 2015-2020 ($ millions)
    • Migraine drugs market in Americas
      • Table Migraine drugs market in Americas 2015-2020 ($ billions)
    • Migraine drugs market in EMEA
      • Table Migraine drugs market in EMEA 2015-2020 ($ millions)
    • Migraine drugs market in APAC
      • Table Migraine drugs market in APAC 2015-2020 ($ millions)
  • Market drivers
    • Growing awareness about migraine and its treatment options
    • Tentative approval of pipeline candidates
    • High unmet needs
    • Increased prevalence of migraines
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Lack of proper diagnosis
      • Table Percentage of population diagnosed with migraine in US 2014
    • Adverse effects of drugs
    • Increased preference for alternative therapies
    • Generic penetration
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Antimigraine devices and headbands
    • Increase in R&D
    • Novel product innovations
    • Strategic alliances
  • Vendor landscape
    • Competitive scenario
    • Allergan
      • Table Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions)
      • Table Allergan: Key takeaways
    • Endo International
      • Table Endo International: Key takeaways
    • GlaxoSmithKline
      • Table GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
    • Impax
      • Table Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions)
      • Table Impax: Key takeaways
    • Pfizer
      • Table Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
      • Table Pfizer: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report